Drug Trial Radar · NCT07009860
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
121
Actual
Start
Jun 16, 2025
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Altimmune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.
Conditions
- Alcohol-associated Liver Disease
Interventions
PemvidutideDrug
Pemvidutide 2.4 mg SC Injection
PlaceboOther
Placebo SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative (%) reduction in liver stiffness by VCTE compared to baselineTime frame: Week 48 and 24
Locations
37 sites in 2 countries. Site status is shown where the registry gives one.
Altimmune Clinical Study Site
Peoria, Arizona
Altimmune Clinical Study Site
Tucson, Arizona
Altimmune Clinical Study Site
North Little Rock, Arkansas
Altimmune Clinical Study Site
Fresno, California
Altimmune Clinical Study Site
La Jolla, California
Altimmune Clinical Study Site
Pasadena, California
Altimmune Clinical Study Site
Bradenton, Florida
Altimmune Clinical Study Site
Doral, Florida
Altimmune Clinical Study Site
Fort Myers, Florida
Altimmune Clinical Study Site
Miami, Florida
Altimmune Clinical Study Site
Miami, Florida
Altimmune Clinical Study Site
Miami Lakes, Florida
Altimmune Clinical Study Site
Naples, Florida
Altimmune Clinical Study Site
Orlando, Florida
Altimmune Clinical Study Site
Atlanta, Georgia
Altimmune Clinical Study Site
Indianapolis, Indiana
Altimmune Clinical Study Site
Louisville, Kentucky
Altimmune Clinical Study Site
Bastrop, Louisiana
Altimmune Clinical Study Site
Marrero, Louisiana
Altimmune Clinical Study Site
West Monroe, Louisiana
Altimmune Clinical Study Site
St Louis, Missouri
Altimmune Clinical Study Site
Las Vegas, Nevada
Altimmune Clinical Study Site
Manhasset, New York
Altimmune Clinical Study Site
New York, New York
Altimmune Clinical Study Site
Syracuse, New York
Altimmune Clinical Study Site
Wilmington, North Carolina
Altimmune Clinical Study Site
Westlake, Ohio
Altimmune Clinical Study Site
Brownsville, Texas
Altimmune Clinical Study Site
Dallas, Texas
Altimmune Clinical Study Site
Edinburg, Texas
Altimmune Clinical Study Site
Houston, Texas
Altimmune Clinical Study Site
Houston, Texas
Altimmune Clinical Study Site
San Antonio, Texas
Altimmune Clinical Study Site
San Antonio, Texas
Altimmune Clinical Study Site
Waco, Texas
Altimmune Clinical Study Site
Seattle, Washington
Altimmune Clinical Study Site
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.